JP2012525385A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012525385A5 JP2012525385A5 JP2012508485A JP2012508485A JP2012525385A5 JP 2012525385 A5 JP2012525385 A5 JP 2012525385A5 JP 2012508485 A JP2012508485 A JP 2012508485A JP 2012508485 A JP2012508485 A JP 2012508485A JP 2012525385 A5 JP2012525385 A5 JP 2012525385A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- disease
- pharmaceutical formulation
- administered
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- LDCRTTXIJACKKU-ONEGZZNKSA-N dimethyl fumarate Chemical compound COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 claims description 22
- 229960004419 dimethyl fumarate Drugs 0.000 claims description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- NKHAVTQWNUWKEO-UHFFFAOYSA-N fumaric acid monomethyl ester Natural products COC(=O)C=CC(O)=O NKHAVTQWNUWKEO-UHFFFAOYSA-N 0.000 claims description 13
- NKHAVTQWNUWKEO-NSCUHMNNSA-N monomethyl fumarate Chemical compound COC(=O)\C=C\C(O)=O NKHAVTQWNUWKEO-NSCUHMNNSA-N 0.000 claims description 13
- 229940005650 monomethyl fumarate Drugs 0.000 claims description 13
- 201000006417 multiple sclerosis Diseases 0.000 claims description 13
- 239000013543 active substance Substances 0.000 claims description 11
- -1 microtablet Substances 0.000 claims description 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims 7
- 239000002775 capsule Substances 0.000 claims 3
- 239000006187 pill Substances 0.000 claims 2
- 206010016825 Flushing Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 239000012669 liquid formulation Substances 0.000 claims 1
- 235000012054 meals Nutrition 0.000 claims 1
- 239000008203 oral pharmaceutical composition Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 45
- 150000001875 compounds Chemical class 0.000 description 33
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 15
- 230000004770 neurodegeneration Effects 0.000 description 15
- 230000003959 neuroinflammation Effects 0.000 description 15
- 208000031277 Amaurotic familial idiocy Diseases 0.000 description 12
- 201000011240 Frontotemporal dementia Diseases 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 206010018341 Gliosis Diseases 0.000 description 7
- 208000037875 astrocytosis Diseases 0.000 description 7
- 230000007341 astrogliosis Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 208000011580 syndromic disease Diseases 0.000 description 7
- 201000011452 Adrenoleukodystrophy Diseases 0.000 description 6
- 101150102665 CCL20 gene Proteins 0.000 description 6
- 101150093802 CXCL1 gene Proteins 0.000 description 6
- 101150077124 CXCL10 gene Proteins 0.000 description 6
- 206010008025 Cerebellar ataxia Diseases 0.000 description 6
- 101150031350 Cxcl2 gene Proteins 0.000 description 6
- 101150102927 Cxcl3 gene Proteins 0.000 description 6
- 208000004986 Diffuse Cerebral Sclerosis of Schilder Diseases 0.000 description 6
- 102000009030 Member 1 Subfamily D ATP Binding Cassette Transporter Human genes 0.000 description 6
- 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 description 6
- 208000021642 Muscular disease Diseases 0.000 description 6
- 201000009623 Myopathy Diseases 0.000 description 6
- 208000021386 Sjogren Syndrome Diseases 0.000 description 6
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 6
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 description 6
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 5
- 206010048804 Kearns-Sayre syndrome Diseases 0.000 description 5
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 101100369986 Mus musculus Tnfaip2 gene Proteins 0.000 description 4
- 101150091206 Nfkbia gene Proteins 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 230000007850 degeneration Effects 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 206010030875 ophthalmoplegia Diseases 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 206010065040 AIDS dementia complex Diseases 0.000 description 3
- 208000007848 Alcoholism Diseases 0.000 description 3
- 208000011403 Alexander disease Diseases 0.000 description 3
- 208000023434 Alpers-Huttenlocher syndrome Diseases 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 206010003591 Ataxia Diseases 0.000 description 3
- 102000014461 Ataxins Human genes 0.000 description 3
- 108010078286 Ataxins Proteins 0.000 description 3
- 208000014644 Brain disease Diseases 0.000 description 3
- 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 description 3
- 208000022526 Canavan disease Diseases 0.000 description 3
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 3
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 3
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 3
- 206010049020 Encephalitis periaxialis diffusa Diseases 0.000 description 3
- 208000032274 Encephalopathy Diseases 0.000 description 3
- 208000024412 Friedreich ataxia Diseases 0.000 description 3
- 208000002339 Frontotemporal Lobar Degeneration Diseases 0.000 description 3
- 101150005894 GCLC gene Proteins 0.000 description 3
- 101150096192 GGT1 gene Proteins 0.000 description 3
- 101150037699 GSTA2 gene Proteins 0.000 description 3
- 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 description 3
- 208000023105 Huntington disease Diseases 0.000 description 3
- 208000027747 Kennedy disease Diseases 0.000 description 3
- 208000028226 Krabbe disease Diseases 0.000 description 3
- 208000009829 Lewy Body Disease Diseases 0.000 description 3
- 201000002832 Lewy body dementia Diseases 0.000 description 3
- 208000016604 Lyme disease Diseases 0.000 description 3
- 208000002569 Machado-Joseph Disease Diseases 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 206010058799 Mitochondrial encephalomyopathy Diseases 0.000 description 3
- 208000001089 Multiple system atrophy Diseases 0.000 description 3
- 208000036572 Myoclonic epilepsy Diseases 0.000 description 3
- 206010052057 Neuroborreliosis Diseases 0.000 description 3
- 208000007125 Neurotoxicity Syndromes Diseases 0.000 description 3
- 208000017493 Pelizaeus-Merzbacher disease Diseases 0.000 description 3
- 208000031845 Pernicious anaemia Diseases 0.000 description 3
- 208000032319 Primary lateral sclerosis Diseases 0.000 description 3
- 102000029797 Prion Human genes 0.000 description 3
- 108091000054 Prion Proteins 0.000 description 3
- 208000024777 Prion disease Diseases 0.000 description 3
- 208000005587 Refsum Disease Diseases 0.000 description 3
- 208000021811 Sandhoff disease Diseases 0.000 description 3
- 208000021235 Schilder disease Diseases 0.000 description 3
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 3
- 101150101311 Sqstm1 gene Proteins 0.000 description 3
- 101150074234 TXNRD1 gene Proteins 0.000 description 3
- 206010043189 Telangiectasia Diseases 0.000 description 3
- 206010044221 Toxic encephalopathy Diseases 0.000 description 3
- 231100000076 Toxic encephalopathy Toxicity 0.000 description 3
- 206010046298 Upper motor neurone lesion Diseases 0.000 description 3
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 description 3
- 208000030597 adult Refsum disease Diseases 0.000 description 3
- 201000007930 alcohol dependence Diseases 0.000 description 3
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 206010008129 cerebral palsy Diseases 0.000 description 3
- 229960003920 cocaine Drugs 0.000 description 3
- 201000009028 early myoclonic encephalopathy Diseases 0.000 description 3
- 201000006061 fatal familial insomnia Diseases 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 101150096281 gsta3 gene Proteins 0.000 description 3
- 208000008675 hereditary spastic paraplegia Diseases 0.000 description 3
- 208000006443 lactic acidosis Diseases 0.000 description 3
- 201000010901 lateral sclerosis Diseases 0.000 description 3
- 210000003470 mitochondria Anatomy 0.000 description 3
- 201000011540 mitochondrial DNA depletion syndrome 4a Diseases 0.000 description 3
- 208000005264 motor neuron disease Diseases 0.000 description 3
- 201000003631 narcolepsy Diseases 0.000 description 3
- 201000001119 neuropathy Diseases 0.000 description 3
- 230000007823 neuropathy Effects 0.000 description 3
- 101150075804 nqo1 gene Proteins 0.000 description 3
- 208000033808 peripheral neuropathy Diseases 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 3
- 210000000278 spinal cord Anatomy 0.000 description 3
- 208000002320 spinal muscular atrophy Diseases 0.000 description 3
- 208000009056 telangiectasis Diseases 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 206010016717 Fistula Diseases 0.000 description 2
- 208000001799 Hereditary Optic Atrophies Diseases 0.000 description 2
- 102100026784 Myelin proteolipid protein Human genes 0.000 description 2
- 206010028570 Myelopathy Diseases 0.000 description 2
- 208000002537 Neuronal Ceroid-Lipofuscinoses Diseases 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 208000024571 Pick disease Diseases 0.000 description 2
- 241000206607 Porphyra umbilicalis Species 0.000 description 2
- 101100240886 Rattus norvegicus Nptx2 gene Proteins 0.000 description 2
- 210000001130 astrocyte Anatomy 0.000 description 2
- 210000003710 cerebral cortex Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 230000003890 fistula Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 208000017476 juvenile neuronal ceroid lipofuscinosis Diseases 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 201000007607 neuronal ceroid lipofuscinosis 3 Diseases 0.000 description 2
- 208000021090 palsy Diseases 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 101150084750 1 gene Proteins 0.000 description 1
- 102000007371 Ataxin-3 Human genes 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 208000014060 Niemann-Pick disease Diseases 0.000 description 1
- 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 230000008741 proinflammatory signaling process Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17379709P | 2009-04-29 | 2009-04-29 | |
| US61/173,797 | 2009-04-29 | ||
| US17527009P | 2009-05-04 | 2009-05-04 | |
| US61/175,270 | 2009-05-04 | ||
| PCT/US2010/001282 WO2010126605A1 (en) | 2009-04-29 | 2010-04-29 | Treatment of neurodegeneration and neuroinflammation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014239565A Division JP2015044855A (ja) | 2009-04-29 | 2014-11-27 | 神経変性および神経炎症の治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012525385A JP2012525385A (ja) | 2012-10-22 |
| JP2012525385A5 true JP2012525385A5 (enExample) | 2013-10-10 |
Family
ID=43032484
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012508485A Withdrawn JP2012525385A (ja) | 2009-04-29 | 2010-04-29 | 神経変性および神経炎症の治療 |
| JP2014239565A Pending JP2015044855A (ja) | 2009-04-29 | 2014-11-27 | 神経変性および神経炎症の治療 |
| JP2016090250A Pending JP2016175926A (ja) | 2009-04-29 | 2016-04-28 | 神経変性および神経炎症の治療 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014239565A Pending JP2015044855A (ja) | 2009-04-29 | 2014-11-27 | 神経変性および神経炎症の治療 |
| JP2016090250A Pending JP2016175926A (ja) | 2009-04-29 | 2016-04-28 | 神経変性および神経炎症の治療 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20120165404A1 (enExample) |
| EP (3) | EP3466420A1 (enExample) |
| JP (3) | JP2012525385A (enExample) |
| CN (2) | CN102427727A (enExample) |
| AU (1) | AU2010242064A1 (enExample) |
| CA (1) | CA2760133A1 (enExample) |
| HK (1) | HK1255133A1 (enExample) |
| NZ (2) | NZ595941A (enExample) |
| WO (1) | WO2010126605A1 (enExample) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19853487A1 (de) | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
| WO2005023241A1 (en) | 2003-09-09 | 2005-03-17 | Fumapharm Ag | The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma |
| SI2801354T1 (sl) * | 2004-10-08 | 2017-07-31 | Forward Pharma A/S | Farmacevtske sestave z nadzorovanim sproščanjem, ki zajemajo ester fumarne kisline |
| DK2653873T3 (da) | 2007-02-08 | 2022-07-25 | Biogen Ma Inc | Sammensætninger og anvendelser til behandling af multipel sklerose |
| PT2139467T (pt) * | 2007-02-08 | 2016-12-16 | Biogen Ma Inc | Neuroproteção em doenças desmielinizantes |
| DK2334378T3 (da) | 2008-08-19 | 2014-07-07 | Xenoport Inc | Prodrugs af methylhydrogenfumarat, farmaceutiske sammensætninger deraf og fremgangsmåder til anvendelse |
| KR101699912B1 (ko) | 2009-01-09 | 2017-01-25 | 포워드 파마 에이/에스 | 1종 이상의 푸마르산 에스테르를 침식 매트릭스에 함유하는 제제 |
| JPWO2010098429A1 (ja) | 2009-02-27 | 2012-09-06 | 国立大学法人大阪大学 | 免疫アジュバント組成物、及びその利用 |
| EP3466420A1 (en) * | 2009-04-29 | 2019-04-10 | Biogen MA Inc. | Dimethyl fumarate for the treatment of friedreich ataxia |
| US20140142095A1 (en) * | 2011-04-28 | 2014-05-22 | Serket Pharma, Llc | Agents useful for treating friedreich's ataxia and other neurodegenerative diseases |
| EP2713724A4 (en) * | 2011-05-26 | 2015-03-11 | Biogen Idec Inc | METHODS OF TREATING MULTIPLE SCLEROSIS AND PRESERVING AND / OR INCREASING MYELINE CONTENT |
| JP6385273B6 (ja) | 2011-06-08 | 2023-12-15 | バイオジェン・エムエイ・インコーポレイテッド | 高純度結晶性ジメチルフマラートの調製方法 |
| HK1202885A1 (en) * | 2011-12-16 | 2015-10-09 | Biogen Ma Inc. | Silicon-containing fumaric acid esters |
| US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
| CN113244185A (zh) * | 2012-02-07 | 2021-08-13 | 比奥根玛公司 | 含有富马酸二甲酯的药物组合物 |
| US20130259856A1 (en) * | 2012-03-27 | 2013-10-03 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate |
| JP2013220090A (ja) * | 2012-04-19 | 2013-10-28 | Tohoku Univ | 眼疾患治療に使用する薬剤スクリーニング方法 |
| JP2015527372A (ja) * | 2012-08-22 | 2015-09-17 | ゼノポート，インコーポレイティド | 副作用を低減させるモノメチルフマレートおよびそのプロドラッグの投与方法 |
| US20140348915A9 (en) | 2012-08-22 | 2014-11-27 | Xenoport, Inc. | Oral Dosage Forms of Methyl Hydrogen Fumarate and Prodrugs Thereof |
| US20140171504A1 (en) | 2012-12-14 | 2014-06-19 | Georgia Regents Research Institute, Inc. | Methods of Treating Sickle Cell Disease and Related Disorders Using Fumaric Acid Esters |
| JP6506174B2 (ja) * | 2012-12-21 | 2019-04-24 | バイオジェン エムエー インコーポレイテッド | 重水素置換されたフマル酸誘導体 |
| CN103173544B (zh) * | 2013-03-05 | 2015-01-28 | 浙江大学 | Leber病之线粒体T3866C检测试剂盒及应用 |
| CN105452213B (zh) | 2013-03-14 | 2017-09-22 | 阿尔克梅斯制药爱尔兰有限公司 | 富马酸酯前体药物及其在治疗多种疾病中的应用 |
| US8669281B1 (en) | 2013-03-14 | 2014-03-11 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
| WO2014160633A1 (en) | 2013-03-24 | 2014-10-02 | Xenoport, Inc. | Pharmaceutical compositions of dimethyl fumarate |
| US9302977B2 (en) | 2013-06-07 | 2016-04-05 | Xenoport, Inc. | Method of making monomethyl fumarate |
| US9421182B2 (en) | 2013-06-21 | 2016-08-23 | Xenoport, Inc. | Cocrystals of dimethyl fumarate |
| TW201516020A (zh) | 2013-09-06 | 2015-05-01 | Xenoport Inc | （ｎ，ｎ－二乙基胺甲醯基）甲基（２ｅ）丁－２－烯－１，４－二酸甲酯之晶形、合成方法及用途 |
| CN103768045B (zh) * | 2013-10-30 | 2015-10-07 | 苏州大学附属第一医院 | 富马酸二甲酯在制备治疗蛛网膜下腔出血后早期脑损伤药物的应用 |
| US20160310457A1 (en) * | 2013-12-12 | 2016-10-27 | Almirall, S.A. | Pharmaceutical compositions comprising dimethyl fumarate |
| CA2940845C (en) | 2014-02-24 | 2019-09-24 | Alkermes Pharma Ireland Limited | Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases |
| US10098863B2 (en) | 2014-02-28 | 2018-10-16 | Banner Life Sciences Llc | Fumarate esters |
| US9636318B2 (en) | 2015-08-31 | 2017-05-02 | Banner Life Sciences Llc | Fumarate ester dosage forms |
| US9326947B1 (en) | 2014-02-28 | 2016-05-03 | Banner Life Sciences Llc | Controlled release fumarate esters |
| EP3110408B1 (en) | 2014-02-28 | 2019-01-16 | Banner Life Sciences LLC | Controlled release enteric soft capsules of fumarate esters |
| US9999672B2 (en) | 2014-03-24 | 2018-06-19 | Xenoport, Inc. | Pharmaceutical compositions of fumaric acid esters |
| MA40990A (fr) * | 2014-11-19 | 2017-09-26 | Biogen Ma Inc | Formulations de matrice pharmaceutique comprenant du fumarate de diméthyle |
| AU2015381240A1 (en) | 2015-02-08 | 2017-07-06 | Alkermes Pharma Ireland Limited | Monomethylfumarate prodrug compositions |
| MA41785A (fr) | 2015-03-20 | 2018-01-23 | Biogen Ma Inc | Procédés et compositions pour l'administration intraveineuse de fumarates pour le traitement de maladies neurologiques |
| WO2017056107A1 (en) * | 2015-09-28 | 2017-04-06 | Natco Pharma Ltd | Pharmaceutical compositions of dimethyl fumarate |
| GR1009149B (el) * | 2016-10-25 | 2017-10-31 | Φαρματεν Αβεε | Φαρμακευτικα σκευασματα που περιλαμβανουν εναν εστερα φουμαρικου οξεως και μεθοδος παραγωγης αυτων |
| JP7084689B2 (ja) * | 2016-12-08 | 2022-06-15 | 公益財団法人東京都医学総合研究所 | 脳組織の異常を伴う非ヒト動物の作製方法およびその利用 |
| MA49448A (fr) | 2017-06-23 | 2020-04-29 | Almirall Sa | Compositions pharmaceutiques contenant du fumarate de diméthyle |
| US11382889B2 (en) * | 2018-04-19 | 2022-07-12 | Institut D'investigació Biomèdica De Bellvitge (Idibell) | NRF2 activators for the prevention and/or treatment of axonal degeneration |
| CN108904779B (zh) * | 2018-09-29 | 2019-12-03 | 南华大学 | 曲普瑞林的新应用 |
| CN109364058A (zh) * | 2018-12-05 | 2019-02-22 | 中南大学湘雅医院 | 富马酸酯及其可药用盐在制备治疗铁死亡相关疾病的药物中的应用 |
| US20220087942A1 (en) | 2019-05-31 | 2022-03-24 | Curacle Co., Ltd. | Enteric tablet containing dimethyl fumarate |
| WO2021092536A1 (en) * | 2019-11-08 | 2021-05-14 | The Children's Hospital Of Philadelphia | Compositions and methods for treating macrophage activation syndrome |
| CN113117081B (zh) * | 2019-12-30 | 2024-12-24 | 上海海洋大学 | ZC3H12b基因或蛋白的用途及一种肝脏疾病动物模型的建立方法 |
| WO2021142062A1 (en) | 2020-01-10 | 2021-07-15 | Banner Life Sciences Llc | Fumarate ester dosage forms with enhanced gastrointestinal tolerability |
| WO2022203432A1 (ko) | 2021-03-25 | 2022-09-29 | 주식회사 큐라클 | 특정 약동학적 매개변수를 나타내는 디메틸푸마레이트를 유효성분으로 함유한 약학적 조성물 |
| CN115487297A (zh) * | 2021-06-17 | 2022-12-20 | 清华大学 | 治疗神经元蜡样质脂褐质沉积症的方法和药物 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19721099C2 (de) | 1997-05-20 | 1999-12-02 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten |
| DE19853487A1 (de) | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
| US6812248B2 (en) * | 2000-07-05 | 2004-11-02 | John Hopkins University School Of Medicine | Prevention and treatment of degenerative diseases by glutathione and phase II detoxification enzymes |
| DE10101307A1 (de) * | 2001-01-12 | 2002-08-01 | Fumapharm Ag Muri | Fumarsäurederivate als NF-kappaB-Inhibitor |
| JP2004041208A (ja) * | 2002-07-15 | 2004-02-12 | Sankyo Co Ltd | インスリン抵抗性改善効果の評価方法 |
| SI2801354T1 (sl) | 2004-10-08 | 2017-07-31 | Forward Pharma A/S | Farmacevtske sestave z nadzorovanim sproščanjem, ki zajemajo ester fumarne kisline |
| WO2006050730A1 (en) | 2004-11-10 | 2006-05-18 | Aditech Pharma Ab | Novel salts of fumaric acid monoalkylesters and their pharmaceutical use |
| WO2007005879A2 (en) * | 2005-07-01 | 2007-01-11 | The Johns Hopkins University | Compositions and methods for the treatment or prevention of disorders relating to oxidative stress |
| US20100144651A1 (en) | 2005-07-07 | 2010-06-10 | Aditech Pharma Ab | Novel glucopyranose esters and glucofuranose esters of alkyl- fumarates and their pharmaceutical use |
| WO2007006307A2 (en) | 2005-07-07 | 2007-01-18 | Aditech Pharma Ab | Novel salts of fumaric acid monoalkylesters and their pharmaceutical use |
| WO2007042035A2 (en) * | 2005-10-07 | 2007-04-19 | Aditech Pharma Ab | Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders |
| US20080299196A1 (en) * | 2005-10-07 | 2008-12-04 | Aditech Pharma Ab | Controlled Release Pharmaceutical Compositions Comprising a Fumaric Acid Ester |
| US20070224638A1 (en) * | 2006-03-27 | 2007-09-27 | Institut Pasteur | Secreted proteins as early markers and drug targets for autoimmunity, tumorigenesis and infections |
| US20080089861A1 (en) * | 2006-07-10 | 2008-04-17 | Went Gregory T | Combination therapy for treatment of demyelinating conditions |
| WO2008039876A1 (en) * | 2006-09-26 | 2008-04-03 | Case Western Reserve University | Cytokine signaling |
| PT2139467T (pt) * | 2007-02-08 | 2016-12-16 | Biogen Ma Inc | Neuroproteção em doenças desmielinizantes |
| DK2653873T3 (da) * | 2007-02-08 | 2022-07-25 | Biogen Ma Inc | Sammensætninger og anvendelser til behandling af multipel sklerose |
| KR101699912B1 (ko) * | 2009-01-09 | 2017-01-25 | 포워드 파마 에이/에스 | 1종 이상의 푸마르산 에스테르를 침식 매트릭스에 함유하는 제제 |
| EP3466420A1 (en) * | 2009-04-29 | 2019-04-10 | Biogen MA Inc. | Dimethyl fumarate for the treatment of friedreich ataxia |
-
2010
- 2010-04-29 EP EP18206136.6A patent/EP3466420A1/en not_active Withdrawn
- 2010-04-29 WO PCT/US2010/001282 patent/WO2010126605A1/en not_active Ceased
- 2010-04-29 JP JP2012508485A patent/JP2012525385A/ja not_active Withdrawn
- 2010-04-29 EP EP17202547.0A patent/EP3318249A1/en not_active Withdrawn
- 2010-04-29 AU AU2010242064A patent/AU2010242064A1/en not_active Abandoned
- 2010-04-29 EP EP10770066A patent/EP2424357A4/en not_active Withdrawn
- 2010-04-29 CN CN2010800215056A patent/CN102427727A/zh active Pending
- 2010-04-29 CA CA2760133A patent/CA2760133A1/en not_active Abandoned
- 2010-04-29 NZ NZ595941A patent/NZ595941A/en not_active IP Right Cessation
- 2010-04-29 NZ NZ617130A patent/NZ617130A/en not_active IP Right Cessation
- 2010-04-29 US US13/266,997 patent/US20120165404A1/en not_active Abandoned
- 2010-04-29 CN CN201410648177.2A patent/CN104523673A/zh active Pending
-
2014
- 2014-11-13 US US14/540,136 patent/US20150132747A1/en not_active Abandoned
- 2014-11-27 JP JP2014239565A patent/JP2015044855A/ja active Pending
-
2016
- 2016-04-28 JP JP2016090250A patent/JP2016175926A/ja active Pending
-
2018
- 2018-11-07 HK HK18114182.9A patent/HK1255133A1/en unknown
- 2018-11-29 US US16/204,076 patent/US20190195860A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20190195860A1 (en) | Treatment of Neurodegeneration and Neuroinflammation | |
| JP6941109B2 (ja) | Ｆｘｒアゴニストを使用するための方法 | |
| ES2797493T3 (es) | Formulaciones farmacéuticas de liberación controlada de nitazoxanida | |
| JP6038653B2 (ja) | 低頻度酢酸グラチラマー治療 | |
| US20140163100A1 (en) | Methods of Treating Multiple Sclerosis and Preserving and/or Increasing Myelin Content | |
| CN110693867A (zh) | 用于治疗代谢性病症的组合物和方法 | |
| CZ299960B6 (cs) | Použití derivátu kyseliny fumarové | |
| EA014189B1 (ru) | Применение флибансерина для лечения расстройств полового влечения в предклимактерический период | |
| JP2021152060A (ja) | アカンプロセートおよびｄ−サイクロセリンを使用する組み合わせ療法 | |
| CA2968980A1 (en) | Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same | |
| TWI226238B (en) | Use of statins to inhibit formation of osteoclasts | |
| CN110167595A (zh) | 非酒精性脂肪性肝病的预防及治疗药 | |
| BRPI0418973A (pt) | composições de risedronato e seus métodos de uso | |
| US20200069716A1 (en) | Treatment of sleep apnea with a combination of a carbonic anhydrase inhibitor and an aldosterone antagonist | |
| JP2007523162A5 (enExample) | ||
| JP2003252795A (ja) | 軽度認知障害治療剤 | |
| MA27157A1 (fr) | Methode de traitement d'affections osseuses. | |
| RU2000109303A (ru) | Производные пиперидинилметилоксазолидинона | |
| JPH07323043A (ja) | 爪の保護剤及び爪の保護剤キット | |
| CA3146794A1 (en) | Use of a benzoate containing composition to treat neurodegenerative disorders | |
| Navarro et al. | P1-418 SUSTAINED DELIVERY OF SURFACE MODIFIED DONEPEZIL HCL LOADED PCL NANOPARTICLES FOR ALZHEIMER’S DISEASE | |
| JP2024541770A5 (enExample) | ||
| CA3213743A1 (en) | Methods of treating neurodegenerative disorders with intranasal nf-kappab essential modifier (nemo)-binding domain (nbd) peptide | |
| JP2005507884A5 (enExample) | ||
| HK40021394A (en) | Compositions and methods for treating metabolic disorders |